17 β－ RNAi agent for inhibiting expression of hsd13 type (hsd17b13), its composition and usage

摘要

This disclosure is β－ Hydroxysteroid dehydrogenase type 13 (hsd17b13 or 17). β－ The present invention relates to an RNAi agent capable of inhibiting gene expression.Disclosed is a pharmaceutical composition comprising hsd17b13 RNAi and its use.The hsd17b13 RNAi agent disclosed herein may be associated with the target ligand and may facilitate delivery to cells including hepatic parenchymal cells.Delivery of hsd17b13 RNAi agents in vivo provides an inhibition of hsd17b13 gene expression.Non alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver fibrosis Hsd17b13 related diseases and disorders may be used in treating treatment of hsd17b13 related diseases and disorders including alcoholic or non-alcoholic fatty liver disease.